scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1042858379 |
P356 | DOI | 10.1038/JID.2012.233 |
P698 | PubMed publication ID | 22832492 |
P5875 | ResearchGate publication ID | 230567972 |
P2093 | author name string | Christine Wagner | |
Gaurav Pathria | |||
Stephan N Wagner | |||
P2860 | cites work | ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas | Q24290531 |
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
Rewired ERK-JNK signaling pathways in melanoma | Q24683737 | ||
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
Genomic analysis of metastasis reveals an essential role for RhoC | Q28144278 | ||
The mammalian Mog1 protein is a guanine nucleotide release factor for Ran | Q28144428 | ||
Identification of a signal for rapid export of proteins from the nucleus | Q29547742 | ||
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma | Q29614282 | ||
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA | Q29620175 | ||
The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain | Q29620270 | ||
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking | Q33890625 | ||
PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells | Q33945648 | ||
NESbase version 1.0: a database of nuclear export signals | Q34169526 | ||
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity | Q34207970 | ||
Nucleocytoplasmic transport: Ran, beta and beyond | Q34446326 | ||
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer | Q34756429 | ||
Nuclear transport and cancer: from mechanism to intervention | Q35633427 | ||
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions | Q36360691 | ||
Identification of nuclear export inhibitors with potent anticancer activity in vivo | Q37081966 | ||
CRM1-mediated nuclear export of proteins and drug resistance in cancer | Q37320237 | ||
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases | Q37375070 | ||
Mdm2-mediated ubiquitylation: p53 and beyond. | Q37508606 | ||
ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence | Q37618297 | ||
Polo-like kinase 1 is a potential therapeutic target in human melanoma | Q39528323 | ||
Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6 | Q39576878 | ||
Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. | Q40005196 | ||
Recurrent patterns of dual RB and p53 pathway inactivation in melanoma | Q40340097 | ||
Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. | Q40549982 | ||
Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line | Q40675789 | ||
Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism | Q40895714 | ||
Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. | Q40911261 | ||
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma | Q40912648 | ||
Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. | Q42066929 | ||
Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. | Q42650781 | ||
Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1 in leptomycin B-inhibited cyclin D1 expression | Q42796003 | ||
Anticancer therapy: boosting the bang of Bim. | Q43252624 | ||
Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal | Q45300833 | ||
Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. | Q45941482 | ||
Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes. | Q46552226 | ||
The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. | Q46668855 | ||
Sef is a spatial regulator for Ras/MAP kinase signaling | Q47235238 | ||
Fisetin: a natural fist against melanoma? | Q48872219 | ||
hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. | Q53581949 | ||
Nuclear export is essential for the tumor-promoting activity of survivin. | Q53588764 | ||
RSK and MSK in MAP kinase signalling | Q58328419 | ||
Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation | Q58376144 | ||
A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals | Q73598439 | ||
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin | Q77851227 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2780-2790 | |
P577 | publication date | 2012-07-26 | |
P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
P1476 | title | Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways | |
P478 | volume | 132 |
Q39677170 | A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. |
Q38812797 | A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds |
Q35206543 | Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines |
Q38207085 | Biological significance of the importin-β family-dependent nucleocytoplasmic transport pathways |
Q35843010 | Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds |
Q55553003 | Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death. |
Q34410193 | Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents |
Q33918079 | KPT-330 has antitumour activity against non-small cell lung cancer |
Q47754114 | Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells |
Q37702556 | Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma |
Q33945804 | Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells |
Q55347484 | Nucleocytoplasmic p27Kip1 Export Is Required for ERK1/2-Mediated Reactive Astroglial Proliferation Following Status Epilepticus. |
Q36774894 | Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells |
Q36489494 | Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. |
Q34778951 | Ran signaling in melanoma: implications for the development of alternative therapeutic strategies |
Q40111489 | RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export |
Q34441666 | SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents |
Q38260357 | Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents |
Q41550563 | Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. |
Q34817365 | Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic |
Q26781513 | Structural Basis of Targeting the Exportin CRM1 in Cancer |
Q35823090 | The Cellular Distribution of RanGAP1 Is Regulated by CRM1-Mediated Nuclear Export in Mammalian Cells |
Q64107227 | The past, present, and future of CRM1/XPO1 inhibitors |
Q37203487 | Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors |
Q53644395 | Visualization of RAS/MAPK Signaling In Situ by the Proximity Ligation Assay (PLA). |